Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
35.9 NOK | -0.28% | +6.53% | -2.97% |
04-25 | Omda AS Announces Board Appointments | CI |
03-01 | Tranche Update on Omda AS (OB:OMDA)'s Equity Buyback Plan announced on January 30, 2023. | CI |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company has a low valuation given the cash flows generated by its activity.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- With an expected P/E ratio at 79.98 and 32.05 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company appears highly valued given the size of its balance sheet.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-2.97% | 66.55M | - | ||
+18.46% | 7.66B | C- | ||
+22.71% | 3.85B | B- | ||
-17.95% | 3.14B | C- | ||
-19.93% | 1.35B | B | ||
-30.65% | 1.18B | - | ||
+4.36% | 934M | C | ||
-34.81% | 911M | - | ||
-26.60% | 840M | - | C+ | |
-15.56% | 726M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- OMDA Stock
- Ratings Omda